Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLC.

J Thorac Oncol · 2016 · PMC5063510 · PMID 27296105

Europe PMC DOI

hedged sentences

0.0660

closest p · 1.3× alpha

0.4470

boldest claim

The sentences

showed a trendp = 0.066so close (0.05 < p ≤ 0.1)

Any autoantibody positivity showed a trend to association with response ( p = 0.066).We then evaluated the association between autoantibody positivity and irPFS.

also in 53,322 other papers

did not reach statistical significancep = 0.447not close (p > 0.1)

Patients receiving PCI had a numerically superior OS (median OS 18.5 versus 12.3 months, respectively), but this difference did not reach statistical significance ( p = 0.447).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.